Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of AnaptysBio's ANB-032?
ANB-032 is a monoclonal antibody commercialized by AnaptysBio, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema). According...
Risk adjusted net present value: What is the current valuation of AnaptysBio's Rosnilimab?
Rosnilimab is a monoclonal antibody commercialized by AnaptysBio, with a leading Phase II program in Ulcerative Colitis. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of AnaptysBio's Imsidolimab?
Imsidolimab is a monoclonal antibody commercialized by AnaptysBio, with a leading Phase III program in Generalized Pustular Psoriasis (GPP). According...
Rosnilimab by AnaptysBio for Vitiligo: Likelihood of Approval
Rosnilimab is under clinical development by AnaptysBio and currently in Phase I for Vitiligo. According to GlobalData, Phase I drugs...
Rosnilimab by AnaptysBio for Graft Versus Host Disease (GVHD): Likelihood of Approval
Rosnilimab is under clinical development by AnaptysBio and currently in Phase I for Graft Versus Host Disease (GVHD). According to...
Rosnilimab by AnaptysBio for Rheumatoid Arthritis: Likelihood of Approval
Rosnilimab is under clinical development by AnaptysBio and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II...
Rosnilimab by AnaptysBio for Ulcerative Colitis: Likelihood of Approval
Rosnilimab is under clinical development by AnaptysBio and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II...